Print pageHome » Memo From Helen Winkle: Reorganization of Office of Generic Drugs
Memo From Helen Winkle: Reorganization of Office of Generic Drugs
PharmaManufacturing.com
08/03/2011
OFFICE OF GENERIC DRUGS
Division of Bioequivalence I
Division of Bioequivalence II
Division of Labeling and Program Support
Division of Microbiology
Division of Clinical Review
Division of Chemistry I
Division of Chemistry II
Division of Chemistry III
Division of Chemistry IV
The reorganization is a major step in CDER's efforts to advance the public health as the use of generic drugs continues to increase.
More News:
-
05/17/2012
Study: US Clears Drugs Faster Than Europe, CanadaFrom WSJ.com
Researchers say the U.S. approved more new medicines in less time than Europe and Canada in the last decade, challenging long-standing criticisms that the Food and Drug Administration lags behind its peers in clearing important new drugs.
-
05/10/2012
Ex-Sanofi Chemist Sentenced To 18 Months For Trade Secrets TheftFrom WSJ.com
A 30-year-old former research chemist for pharmaceutical firm Sanofi was sentenced to 18 months in prison for stealing Sanofi trade secrets and making them available through another company, the U.S. Department of Justice said.
-
04/27/2012
Novo Nordisk Expanding U.S. Workforce 15 Percent
Most new positions are in sales and management, but manufacturing jobs will be added in Clayton, N.C.
-
04/26/2012
AstraZeneca’s Brennan to Retire; Lowth Named Interim CEOFrom Bloomberg.com
AstraZeneca Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
-
04/19/2012
Congress Pushing to Allow Generic Drug Manufacturers to Make Label ChangesFrom Pharmalot
The U.S. Congress has introduced bills that would allow generic makers to make updates to labels as new safety and efficacy information becomes available.
- 04/18/2012 GSK Shifts to Unassigned Seating in RTP Offices
- 04/17/2012 Amgen CEO Comes Clean: I Was Arrogant and an Awful Listener
- 04/16/2012 Product News: Growth Direct Systems for Environmental Monitoring and Sterility
-
04/12/2012
J&J Fined $1.2 Billion in Drug CaseFrom NYTimes.com
A judge in Arkansas ordered Johnson & Johnson and a subsidiary to pay more than $1.2 billion in fines on Wednesday, a day after a jury found that the companies had minimized or concealed the dangers associated with an antipsychotic drug.
- 04/11/2012 Humira Set to Become World's Top-Selling Drug
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
